Bayer Aktiengesellschaft

Bayeraktiengesellschaft

Troponwerke Gmbh & Co Kg

Troponwerke Gmbh & Co.

Baker Aktiengesellschaft

Bodo Junge

Rudolf Schohe-Loop

Thomas Glaser

Hans-Georg Heine

Henning Sommermeyer

Klaus Urbahns

Reilinde Wittka

Jean-Marie-Viktor De Vry

Teunis Schuurman

Heinrich Meier

Zhan Gao

Wolfgang Hartwig

Bernard Schmidt

Maarten De Jonge

Jorg Traber

Lutz Muller

Siegfried Goldmann

Walter Puls

Peter-Rudolf Seidel

Jurgen Stoltefuss

Hartmund Wollweber

Wolfgang Dompert

Rudolf Schohe

Ulrich Benz

Hans P Krause

Bernd Richter

Peter Fey

Egbert Wehinger

Horst Boshagen

Joachim Mittendorf

Ulrich Niewohner

George S Allen

Johannes Kaulen

Kai Van Laak

Jean-Marie Viktor De Vry

Elisabeth Perzborn

Delf Schmidt

Friedel Seuter

Arnold Paessens

Gunter Thomas

Volker-Bernd Fiedler

Frank Mauler

Franz-Peter Hoever

Rudiger Sitt

Otto Behner

Hans-Peter Krause

Jean M De Vry

Jean Marie Viktor De Vry

Matthias Schuller

Jean-Marie V De Vry

Horst Meyer

Friedrich Bossert

Wulf Vater

Stanislav Kazda

Kurt Stoepel

Harald Horstmann

Peter Stadler

Oswald Lockhoff

Werner Frommer

Arend Heise

Gunther Kinast

Bernward Garthoff

Karl-Heinz Boltze

Bernhard Pelster

Hans-Georg Opitz

Uwe Keup

Margaret A Davies

J Org Traber

Novel phenyl-substituted 1,4-dihydropyridines, prepared by reacting halogenophenyl-aldehydes with &bgr;-ketoesters, if appropriate with isolation of the ylidene compounds and enamines. The substances can be employed as active compounds in medicaments, in particular in cerebrally active compositions.

Phenyl-substituted 1,4-dihydropyridines

The invention relates to the use of 5-substituted pyridine- and hexahydroquinoline-3-carboxylic acid derivatives, some of which are known, for the production of medicaments, in particular for the treatment of cerebral disorders.

Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system

The present invention relates to the new use of 1,2-bridged 1,4-dihydropyridines which are known in some cases, of the general formula (I) ##STR1## in which R.sup.1 to R.sup.4 and a have the meaning indicated in the description, processes for their preparation and their use as medicaments, as selective potassium channel modulators, in particular for the treatment of the central nervous system.

Use of 1,2-Bridged 1,4-dihydropyridines as medicaments

The present invention relates to new 2,3-bridged 1,4-dihydropyridines of the general formula (I), ##STR1## in which R, R.sup.1, R.sup.2, D and E have the meaning given in the description, processes for their preparation and their use as medicaments, preferably for treatment of the central nervous system.

2,3-bridged 1,4-dihydropyridines, and their use as medicaments

4-Phenyl-3-substituted 1,4-dihydropyridine esters are prepared by reaction of benzaldehydes with ketoesters and enamines, if appropriate with isolation of the ylidene intermediate products, or by esterification of corresponding dihydropyridinecarboxylic acids with alcohols. The new 4-phenyl-3-substituted 1,4-dihydropyridine esters can be employed as active compounds in medicaments for the treatment of the central nervous system, in particular as cerebral therapeutics.

4-phenyl-3-substituted 1,4-dihydropyridine esters

4-Heterocyclyl-substituted dihydropyridines are prepared by reacting appropriate aldehydes with .beta.-keto esters and aminocrotonic acid esters, or by esterifying 4-heterocyclyl-substituted dihydropyridinecarboxylic acids. The 4-heterocyclyl-substituted dihydropyridines can be employed in medicaments, in particular for the treatment of disorders of the central nervous system.

Heterocyclyl substituted dihydropyridines

Use of 1,2-bridged 1,4-dihydropyridines as medicaments

Diseases characterized by disturbances of the serotoninergic system, psychoses and depression are treated by administration of an aminomethyl-chroman of the formula ##STR1##

2-aminomethyl-chromans effective in the treatment of psychoses and

The present invention relates to the use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters, some of which are known, of the general formula (I) ##STR1## in which A and R.sup.1 -R.sup.3 have the meaning given in the description, as medicaments, in particular for treatment of the central nervous system, and new selected active compounds.

Use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters as medicaments

The present invention relates to a new highly selective process for the preparation of enantiomerically pure halogeno-phenyl-substituted 1,4-dihydropyridine-3,5-dicarboxylic esters of the general formula (I) ##STR1## in which R.sup.1 to R.sup.3 have the meanings given in the description.

Highly selective process for the preparation of enantiomerically pure

Use of substituted 6-amino-4H-pyrans

Use of N-substituted phenothiazines

The substituted 4H-pyrans are prepared by reacting either aldehydes or ylidene compounds with suitably substituted .beta.-diketones. The substituted 4H-pyrans according to the invention are suitable as active compounds in medicaments, in particular for the treatment of disorders of the central nervous system.

Substituted 4H-pyrans

Growing community of inventors

Wuppertal, Germany

Bodo Junge